Clinical Trials Logo
  1. Home
  2. Dengue Fever
  3. NCT01254422

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever Clinical Trial

Official title:
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Clinical Trial Summary

The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia. Primary Objectives: - To describe the safety (in terms of solicited and unsolicited adverse events) of the CYD dengue vaccine in all participants after each injection. - To describe the antibody response to each dengue virus serotype post-injection 2 and post-injection 3.

Clinical Trial Description

Healthy participants aged 2 to 11 years received 3 vaccinations at pre-determined schedules and were followed-up for at least 6 months after the last vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01254422
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 3
Start date December 2, 2010
Completion date January 2013
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04514107 - A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) N/A
Completed NCT00788151 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Phase 2
Completed NCT02510638 - The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia N/A
Completed NCT01666652 - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Completed NCT01443247 - Role of Andi-d in Dengue Fever: a Pilot Study N/A
Completed NCT00831012 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Phase 1
Completed NCT00089908 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Phase 1
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT01134263 - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Phase 3
Completed NCT02741128 - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Phase 2
Completed NCT03620487 - Detection of Dengue Virus in Plasma of Patients in Nepal
Recruiting NCT02608047 - Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou N/A
Completed NCT02510690 - Factors Associated With Poor Dengue Outcomes in Malaysia N/A
Completed NCT01550016 - International Research Consortium on Dengue Risk Assessment, Management, and Surveillance N/A
Completed NCT01421732 - Laboratory Diagnosis and Prognosis of Severe Dengue N/A
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT01224639 - Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Phase 1
Completed NCT01943825 - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Phase 2
Active, not recruiting NCT03465254 - Dengue Serostatus Study in the Philippines